Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 4/20 | 0.50 |
| ▸ | MGAM | O43451 | 6/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512806 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL13207905 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL12711208 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL187278 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL1055883 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL21388397 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL13058696 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL12735687 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| SCHEMBL2511997 | 1.00 | — | — | |
| Inositol SCHEMBL2422938 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12226488-B2 | Nitroreductase-releasable pro-drugs and methods for using the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-02-18 | — | — | US | claimed |
| EP-3542810-B1 | COMPOSITION CONTAINING ARTEMISIA ANNUA EXTRACT AS EFFECTIVE INGREDIENT FOR ALLEVIATING SKIN DISEASE AND PREPARATION METHOD THEREFOR | KOREA INST SCI & TECH (KR) | 2023-05-24 | — | — | EP | claimed |
| EP-4076403-A1 | GASTRO-RESISTANT MICROPARTICLES COMPRISING INOSITOL AND/OR GYMNEMA SYLVESTRE EXTRACT, PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | IDI Integratori Dietetici Italiani S.r.l. (IT) | 2022-10-26 | — | — | EP | claimed |
| EP-4034092-A1 | SCYLLO-INOSITOL AND ITS USE AS INSULIN SENSITIZER | Société des Produits Nestlé S.A. (CH) | 2022-08-03 | — | — | EP | claimed |
| US-20220211854-A1 | NITROREDUCTASE-RELEASABLE PRO-DRUGS AND METHODS FOR USING THE SAME | ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA, A BODY CORPORATE (US) | 2022-07-07 | — | — | US | claimed |
| EP-4021429-A1 | SCYLLO-INOSITOL AND B-CELL MEDIATED DISORDERS | Société des Produits Nestlé S.A. (CH) | 2022-07-06 | — | — | EP | claimed |
| US-20220144747-A1 | SHIKIMATE ANALOGUES AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2022-05-12 | — | — | US | claimed |
| WO-2022081521-A1 | INOSITOL-BISPYROPHOSPHATE-DERIVED COMPOUNDS AND USES THEREOF | NICOLAU YVES CLAUDE (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2021124244-A1 | GASTRO-RESISTANT MICROPARTICLES COMPRISING INOSITOL AND/OR GYMNEMA SYLVESTRE EXTRACT, PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | IDI INTEGRATORI DIETETICI ITALIANI S.R.L. (IT) | 2021-06-24 | — | — | WO | claimed |
| WO-2021058628-A1 | SCYLLO-INOSITOL AND ITS USE AS INSULIN SENSITIZER | Société des Produits Nestlé SA (CH) | 2021-04-01 | — | — | WO | claimed |
| WO-1998057620-A2 | INOSITOL FOR MODULATION OF IMMUNE RESPONSE | CEDARS-SINAI MEDICAL CENTER (US) | 1998-12-23 | — | — | WO | claimed |
| WO-1997034853-A1 | PHOSPHORYLATION PROCESS AND CATALYST | PERSTORP AB (SE) | 1997-09-25 | — | — | WO | claimed |
| EP-0505452-B1 | USE OF INOSITOLPHOSPHATES FOR PREPARING MEDICAMENT | PERSTORP AB (SE) | 1996-06-19 | — | — | EP | claimed |
| EP-0663915-A1 | SYNTHESES OF D-CHIRO-3-INOSOSE AND (+)-D-CHIRO-INOSITOL | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1995-07-26 | — | — | EP | claimed |
| WO-1994007897-A1 | SYNTHESES OF D-CHIRO-3-INOSOSE AND (+)-D-CHIRO-INOSITOL | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1994-04-14 | — | — | WO | claimed |
| US-5217959-A | Method of treating multiple sclerosis with phytic acid | JARIWALLA, RAXIT | 1993-06-08 | — | — | US | claimed |
| US-5112814-A | Method of treatment of Parkinson's disease using phytic acid | SABIN ROBERT (US) | 1992-05-12 | — | — | US | claimed |
| EP-0420428-A2 | Mehod of treatment of rheumatoid arthritis using phytic acid | Sabin, Robert (US) | 1991-04-03 | — | — | EP | claimed |
| US-4952396-A | OR SALTS OR HYDROLYZATES; ORAL ADMINISTRATION | LINUS PAULING INSTITUTE OF SCIENCE & MEDICINE (US) | 1990-08-28 | — | — | US | claimed |
| US-4847082-A | Method of treatment of Alzheimer's disease using phytic acid | Sabin, Robert (US) | 1989-07-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12226488-B2 | Nitroreductase-releasable pro-drugs and methods for using the same | AKR1B1, AKR1A1, POR | LMNA 1971/4885APP 3921/4885GBA1 3358/4885 |
| US-20220211854-A1 | NITROREDUCTASE-RELEASABLE PRO-DRUGS AND METHODS FOR USING THE SAME | AKR1B1, AKR1A1, POR | LMNA 1971/4885APP 3921/4885GBA1 3358/4885 |
| US-20220144747-A1 | SHIKIMATE ANALOGUES AND METHODS OF USE | GRIK5, GRIK1, GRIK3 | LMNA 4673/4885APP 2388/4885GBA1 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.